Evidence map›Paper›PMID 25174030›Full record

ArticleJournal of the National Cancer Institute. Monographs2014

Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sézary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Briseis Aschebrook-Kilfoy, Pierluigi Cocco, Carlo La Vecchia, Ellen T Chang, Claire M Vajdic, Marshall E Kadin, John J Spinelli, Lindsay M Morton, Eleanor V Kane, Joshua N Sampson and 4 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of the National Cancer Institute. Monographs, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 3 syntheses or guidelines pooled it, 53 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Update on T-Cell Lymphoma Epidemiology.Current hematologic malignancy reports · 2024
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Epidemiology of Non-Hodgkin's Lymphoma.Medical sciences (Basel, Switzerland) · 2021
    Review
  17. Article
  18. Sézary Syndrome: Clinical and Biological Aspects.Current hematologic malignancy reports · 2016
    Review
  19. T-cell Lymphoma Epidemiology: the Known and Unknown.Current hematologic malignancy reports · 2016
    Review
  20. Comprehensive Evaluation of Medical Conditions Associated with Risk of Non-Hodgkin Lymphoma using Medicare Claims ("MedWAS").Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 5 countries.

Briseis Aschebrook-KilfoyDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Pierluigi CoccoDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Carlo La VecchiaDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Ellen T ChangDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Claire M VajdicDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Marshall E KadinDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
John J SpinelliDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Lindsay M MortonDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Eleanor V KaneDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Joshua N SampsonDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Carol KastenDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Andrew L FeldmanDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Sophia S WangDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ).
Yawei ZhangDepartment of Health Studies, University of Chicago, Chicago, IL (BA-K); Department of Public Health, Clinical and Molecular Medicine, Occupational Health Section, University of Cagliari, Cagliari, Italy (PC); Dipartimento di Epidimologia, IRCCS- Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, Community Health, University of Milan, Milan, Italy (CLV); Health Sciences Practice, Exponent, Inc., Menlo Park, CA, Department of Health Research and Policy, Stanford University, Stanford, CA (ETC); Prince of Wales Clinical School, University of New South Wales, Sydney, Australia (CMV); Department of Dermatology, Boston University, Boston, MA, Roger Williams Medical Center, Providence, RI (MEK); Cancer Control Research, BC Cancer Agency, Vancouver, BC, Canada, School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (JJS); Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health Bethesda, MD (LMM, JNS); Epidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK (EVK); Biostatistics Center, Massachusetts General Hospital, Boston, MA (CK); Department of Laboratory Medicine and Pathology, Mayo Clinic Cancer Center, Rochester, MN (ALF); Division of Cancer Etiology, Department of Population Sciences, Beckman Research Institute of the City of Hope, Duarte, CA (SSW); Department of Environmental Health Sciences, Yale School of Public Health, New Haven, CT (YZ). yawei.zhang@yale.edu.
Mario Negri Institute for Pharmacological Research · ITIstituti di Ricovero e Cura a Carattere Scientifico · ITNational Institutes of Health · USRoger Williams Medical Center · USUniversity of Chicago · USUniversity of York · GBUNSW Sydney · AUYale University · US

Funding

The Role of Monocytes in non-Hodgkin LymphomaP50CA097274 · NCI · UNIVERSITY OF IOWA · PI WEINER, GEORGE J. · 2002 to 2021
$45.7M
UNIVERSITY OF ROCHESTER'S RESEARCH ASSOCIATE ORGANIZATIONUL1RR024160 · NCRR · UNIVERSITY OF ROCHESTER · PI PEARSON, THOMAS ARTHUR · 2006 to 2011
$38.7M
SPORE in LymphomaP50CA130805 · NCI · UNIVERSITY OF ROCHESTER · PI FISHER, RICHARD I · 2008 to 2012
$11.7M
Multidisciplinary Studies of LymphomaZIACP010170 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MORTON, LINDSAY · 2009 to 2025
$10.7M
Genetic Epidemiology of Chronic Lymphocytic LeukemiaU01CA118444 · NCI · MAYO CLINIC ROCHESTER · PI SLAGER, SUSAN L · 2006 to 2015
$7.1M
Molecular Epidemiology of non Hodgkin's LymphomaR01CA087014 · NCI · UNIVERSITY OF CALIFORNIA SAN FRANCISCO · PI HOLLY, ELIZABETH A. · 2001 to 2005
$6.7M
Molecular Epidemiology of NHL and CLLR01CA092153 · NCI · MAYO CLINIC ROCHESTER · PI CERHAN, JAMES R · 2003 to 2012
$6.7M
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS--SEERN01PC065064 · PC · WAYNE STATE UNIVERSITY · PI WEISS, LINDA K · 1996 to 2000
$4.5M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067008 · PC · UNIVERSITY OF IOWA · PI LYNCH, CHARLES · 1996 to 2000
$3.8M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067009 · PC · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1996 to 2000
$3.0M
A Genome-Wide Association Study of Non-Hodgkin LymphomaR01CA122663 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI SKIBOLA, CHRISTINE F. · 2006 to 2010
$2.7M
Genetic Susceptibility to Non-Hodgkins LymphomaR01CA104682 · NCI · UNIVERSITY OF CALIFORNIA BERKELEY · PI SKIBOLA, CHRISTINE F. · 2003 to 2012
$2.6M
CIHRIntramural NIH HHSNCI NIH HHS 5R01 CA69669-02NCI NIH HHS CA143947NCI NIH HHS CA150037NCI NIH HHS CA165923NCI NIH HHS CA51086NCI NIH HHS CA62006NCI NIH HHS K23 CA102216NCI NIH HHS N01 CO012400NCI NIH HHS N01-CO-12400NCI NIH HHS N01-CP-95618NCI NIH HHS N01-CP-ES-11027NCI NIH HHS N01 PC065064NCI NIH HHS N01 PC067008NCI NIH HHS N01 PC067009NCI NIH HHS N01 PC067010NCI NIH HHS N01-PC-65064NCI NIH HHS N01-PC-67008NCI NIH HHS N01-PC-67009NCI NIH HHS N01-PC-67010NCI NIH HHS N02-PC-71105NCI NIH HHS P50 CA097274NCI NIH HHS P50 CA130805NCI NIH HHS P50 CA97274NCI NIH HHS R01 CA045614NCI NIH HHS R01 CA051086NCI NIH HHS R01 CA062006NCI NIH HHS R01 CA087014NCI NIH HHS R01CA087014NCI NIH HHS R01 CA092153NCI NIH HHS R01 CA100555NCI NIH HHS R01CA100555NCI NIH HHS R01 CA104682NCI NIH HHS R01CA104682NCI NIH HHS R01 CA122663NCI NIH HHS R01CA122663NCI NIH HHS R01 CA14690NCI NIH HHS R01 CA154643NCI NIH HHS R01CA154643-01A1NCI NIH HHS R01CA45614NCI NIH HHS R01 CA50850NCI NIH HHS R01 CA92153NCI NIH HHS R01CA92153-S1NCI NIH HHS R03CA125831NCI NIH HHS R03 CA132153NCI NIH HHS R03CA132153NCI NIH HHS R03 CA143947NCI NIH HHS R03 CA150037NCI NIH HHS R13 CA159842NCI NIH HHS R13 CA159842 01NCI NIH HHS R21 CA165923NCI NIH HHS U01 CA118444NCRR NIH HHS UL 1 RR024160NHLBI NIH HHS T32 HL007152NIAID NIH HHS R01 AI050850NIDA NIH HHS R01 DA014690NIDCD NIH HHS R01 DC014690NIEHS NIH HHS K22 ES011027
6 · The paper itself

Abstract

backgroundMycosis fungoides and Sézary syndrome (MF/SS) are rare cutaneous T-cell lymphomas. Their etiology is poorly understood.

methodsA pooled analysis of 324 MF/SS cases and 17217 controls from 14 case-control studies from Europe, North America, and Australia, as part of the International Lymphoma Epidemiology Consortium (InterLymph) Non-Hodgkin Lymphoma (NHL) Subtypes Project, was carried out to investigate associations with lifestyle, medical history, family history, and occupational risk factors. Multivariate logistic regression models were used to calculate odds ratios (OR) and 95% confidence intervals (CI).

resultsWe found an increased risk of MF/SS associated with body mass index equal to or larger than 30 kg/m(2) (OR = 1.57, 95% CI = 1.03 to 2.40), cigarette smoking for 40 years or more (OR = 1.55, 95% CI = 1.04 to 2.31), eczema (OR = 2.38, 95% CI = 1.73 to 3.29), family history of multiple myeloma (OR = 8.49, 95% CI = 3.31 to 21.80), and occupation as crop and vegetable farmers (OR = 2.37, 95% CI = 1.14 to 4.92), painters (OR = 3.71, 95% CI = 1.94 to 7.07), woodworkers (OR = 2.20, 95% CI = 1.18 to 4.08), and general carpenters (OR = 4.07, 95% CI = 1.54 to 10.75). We also found a reduced risk of MF/SS associated with moderate leisure time physical activity (OR = 0.46, 95% CI = 0.22 to 0.97).

conclusionsOur study provided the first detailed analysis of risk factors for MF/SS and further investigation is needed to confirm these findings in prospective data and in other populations.

Indexed as

Life StyleOccupational ExposureAdultAgedAged, 80 and overAustraliaCase-Control StudiesComorbidityEuropeFemaleHumansMaleMiddle AgedMycosis FungoidesNorth AmericaOdds Ratio

Identifiers

PMID25174030
PMCPMC4155463
OpenAlexW2127360582

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.